Home LiteratureArticle Details
PMID: 16403733 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets.

Albini A, Dell'Eva R, Vené R, Ferrari N, Buhler DR, Noonan DM, Fassina G

Abstract

Xanthohumol (XN), the principal flavonoid of the hop plant (Humulus lupulus L.) and a constituent of beer, has been suggested to have potential cancer chemopreventive activities. We have observed that most cancer chemopreventive agents show antiangiogenic properties in vitro and in vivo, a concept we termed "angioprevention." Here we show for the first time that XN can inhibit growth of a vascular tumor in vivo. Histopathology and in vivo angiogenesis assays indicated that tumor angiogenesis inhibition was involved. Further, we show the mechanisms for its inhibition of angiogenesis in vivo and related endothelial cell activities in vitro. XN repressed both the NF-kappaB and Akt pathways in endothelial cells, indicating that components of these pathways are major targets in the molecular mechanism of XN. Moreover, using in vitro analyses, we show that XN interferes with several points in the angiogenic process, including inhibition of endothelial cell invasion and migration, growth, and formation of a network of tubular-like structures. Our results suggest that XN can be added to the expanding list of antiangiogenic chemopreventive drugs whose potential in cancer prevention and therapy should be evaluated.

MeSH Terms
3T3 Cells/metabolism Administration, Oral Angiogenesis Inhibitors/pharmacology Animals Apoptosis/drug effects Cell Division/drug effects Cell Line, Transformed/drug effects Cell Movement/drug effects Chemotaxis/drug effects Collagen Culture Media, Conditioned/pharmacology Drug Combinations Drug Screening Assays, Antitumor Endothelial Cells/drug effects,metabolism,ultrastructure Endothelium, Vascular/drug effects Flavonoids Humans Humulus/chemistry I-kappa B Proteins/metabolism Laminin Mice Mice, Nude Morphogenesis/drug effects NF-KappaB Inhibitor alpha NF-kappa B/antagonists & inhibitors Neoplasm Transplantation Phosphorylation/drug effects Propiophenones/pharmacology Protein Processing, Post-Translational/drug effects Protein Transport/drug effects Proteoglycans Proto-Oncogene Proteins c-akt/antagonists & inhibitors Sarcoma, Kaposi/blood supply,drug therapy,pathology
Chemicals
Angiogenesis Inhibitors Culture Media, Conditioned Drug Combinations Flavonoids I-kappa B Proteins Laminin NF-kappa B NFKBIA protein, human Nfkbia protein, mouse Propiophenones Proteoglycans matrigel NF-KappaB Inhibitor alpha Collagen Proto-Oncogene Proteins c-akt xanthohumol
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Albini Adriana
Molecular Oncology Laboratory, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy.
Dell'Eva Raffaella
Vené Roberta
Ferrari Nicoletta
Buhler Donald R
Noonan Douglas M
Fassina Gianfranco
Article Info
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
Abbr.
FASEB J
ISSN
1530-6860
Published
2006-03-00
Epub
2005-00-30
Pages
527-9
Language
English
Region
United States
NLM ID
8804484
Subset
IM
Grants
NIEHS NIH HHS · ES000210 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com